Petros Pharmaceuticals, Inc.

PTPISEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1815903

Concept	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	$5.8M	$6.0M	$7.8M	$9.6M
Cost of Goods and Services Sold	$1.6M	$2.3M	$1.6M	$4.0M
Gross Profit	$4.2M	$3.7M	$6.2M	$5.5M
Research and Development Expense	$2.4M	$1.7M	$1.8M	$459.6K
Selling, General and Administrative Expense	$9.3M	$12.2M	$15.6M	$15.7M
Operating Expenses	$17.8M	$23.6M	$24.3M	$22.8M
Operating Income (Loss)	-$13.6M	-$19.9M	-$18.0M	-$17.3M
Other Nonoperating Income (Expense)	$5.5M	-$121.8K	—	—

Concept	FY2024	FY2023	FY2022	FY2021
Assets	$33.8M	$32.4M	$67.4M	$69.9M
Assets, Current	$20.4M	$14.7M	$30.5M	$25.9M
Cash and Cash Equivalents, at Carrying Value	$13.3M	$13.3M	$23.8M	$17.1M
Accounts Receivable, after Allowance for Credit Loss, Current	$2.2M	$2.1M	$2.5M	$5.2M
Inventory, Net	$1.6M	$1.8M	$519.6K	$760.5K
Liabilities	$21.3M	$15.7M	$31.8M	$52.4M
Liabilities, Current	$10.8M	$7.1M	$31.0M	$41.9M
Accounts Payable, Current	$1.7M	$1.8M	$4.6M	—
Stockholders' Equity Attributable to Parent

Concept	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$7.6M	-$12.8M	-$11.9M	-$15.3M
Net Cash Provided by (Used in) Investing Activities	-$24.6K	—	—	-$4.6K
Net Cash Provided by (Used in) Financing Activities	$11.5M	-$1.6M	$18.6M	$30.3M
Payments to Acquire Property, Plant, and Equipment	$24.6K	—	—	$4.6K

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)